Supernus Pharmaceuticals, Inc. (SUPN)
29.72
+0.52
(+1.78%)
USD |
NASDAQ |
Nov 13, 16:00
29.30
-0.42
(-1.41%)
After-Hours: 19:59
Supernus Pharmaceuticals Net Income (Quarterly) : 20.91M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 20.91M |
| June 30, 2026 | -58.37M |
| March 31, 2026 | -2.293M |
| December 31, 2025 | -4.105M |
| September 30, 2025 | -45.12M |
| June 30, 2025 | 22.50M |
| March 31, 2025 | -11.83M |
| December 31, 2024 | 15.33M |
| September 30, 2024 | 38.50M |
| June 30, 2024 | 19.92M |
| March 31, 2024 | 0.124M |
| December 31, 2023 | 1.175M |
| September 30, 2023 | -15.98M |
| June 30, 2023 | -0.831M |
| March 31, 2023 | 16.95M |
| December 31, 2022 | 25.48M |
| September 30, 2022 | 1.749M |
| June 30, 2022 | 7.865M |
| March 31, 2022 | 25.62M |
| December 31, 2021 | 2.442M |
| September 30, 2021 | 21.56M |
| June 30, 2021 | 23.73M |
| March 31, 2021 | 5.694M |
| December 31, 2020 | 30.77M |
| September 30, 2020 | 40.00M |
| Date | Value |
|---|---|
| June 30, 2020 | 34.67M |
| March 31, 2020 | 21.52M |
| December 31, 2019 | 33.13M |
| September 30, 2019 | 28.86M |
| June 30, 2019 | 32.73M |
| March 31, 2019 | 18.34M |
| December 31, 2018 | 25.89M |
| September 30, 2018 | 28.01M |
| June 30, 2018 | 30.74M |
| March 31, 2018 | 26.35M |
| December 31, 2017 | 13.66M |
| September 30, 2017 | 15.96M |
| June 30, 2017 | 17.37M |
| March 31, 2017 | 10.30M |
| December 31, 2016 | 14.32M |
| September 30, 2016 | 61.83M |
| June 30, 2016 | 10.25M |
| March 31, 2016 | 4.825M |
| December 31, 2015 | 6.852M |
| September 30, 2015 | 4.222M |
| June 30, 2015 | 2.437M |
| March 31, 2015 | 0.738M |
| December 31, 2014 | 4.354M |
| September 30, 2014 | 27.86M |
| June 30, 2014 | 3.202M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 32.72M |
| Prestige Consumer Healthcare, Inc. | 25.30M |
| Structure Therapeutics, Inc. | -145.14M |
| Corcept Therapeutics, Inc. | 124.49M |
| Veru, Inc. | -6.988M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 226.77M |
| Total Expenses (Quarterly) | 205.86M |
| EPS Diluted (Quarterly) | 0.3516 |
| Enterprise Value | 1.408B |
| Gross Profit Margin (Quarterly) | 77.67% |
| Profit Margin (Quarterly) | 9.22% |
| Earnings Yield | -2.57% |
| Operating Earnings Yield | 0.77% |
| Normalized Earnings Yield | -0.0306 |